BRAIN CANCER

In an interview with Targeted Oncology, Stephanie Weiss, MD, reviewed the treatment landscape for HER2-positive metastatic breast cancer and gave her predictions on how the paradigm will evolve for patients with brain metastases now that tucatinib has demonstrated efficacy.

In the first pooled prospective study to show the long-term outcomes of cranial radiation in patients with limited brain metastases, it was observed that whole-brain radiotherapy was associated with worse cognitive outcomes and mixed quality of life compared with stereotactic radiosurgery for these patients over time, according to a presentation from Joshua Palmer, MD, at the 2020 Virtual Conference on Brain Metastases.

Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases.

Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib in combination with trastuzumab and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB trial.

David Roberge, MD, discusses the current role of radiosurgery in the brain metastasis treatment paradigm, a topic he reviewed during a presentation at the 2020 Society of Neuro-Oncology Conference on Brain Metastases.

A completed Biologics License Application was submitted to the FDA for omburtamab, an investigation monoclonal antibody, which is intended for the treatment of pediatric patients with central nervous system/leptomeningeal metastasis from neuroblastoma.

In an interview with Targeted Oncology, David Reardon, MD, discussed the background and findings for the phase 1/2 clinical trial of INO-5401 and INO-9012 plus cemiplimab in patients with newly diagnosed glioblastoma.

David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.

Enzastaurin, a first-in-class small molecule, has been granted a Fast Track designation by the FDA for the potential treatment of patients with newly diagnosed glioblastoma.

In an interview with Targeted Oncology, Macarena de la Fuente, MD, discussed the findings from a phase 1b/2 study of olutasidenib as treatment of patients with relapsed/refractory IDH1-mutated gliomas, either alone or in combination with azacitidine.

The FDA granted Fast Track designation to the glutamate-binding molecule, anhydrous enol-oxaloacetate, for the treatment of patients with newly diagnosed glioblastoma multiforme.

A rolling Biologics License Application has been initiated for omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma

Treatment of glioblastoma has seen few advancements since the approval of temozolomide plus radiotherapy in 2005 for newly diagnosed disease. Recently, promising clinical data have reinvigorated hope for novel therapies in this tumor type.

"Breakthrough designation for the companion diagnostic is a big step forward in our endeavor to ensure that more clinicians can have quicker access to comprehensive genomic information."

Glioblastoma currently has a dismal survival rate of only 14.6 months from its diagnosis. We believe berubicin, which based on limited clinical data appears to be the first anthracycline to cross over the blood-brain barrier in adults, provides a potentially novel therapy for the treatment of malignant gliomas.

"We believe that the FDA’s acceptance of our BLA for priority review of our first leading antibody compound, naxitamab, is a significant achievement for Y-mAbs and a crucial step forward as we anticipate that naxitamab if approved, can address a significant unmet medical need for [patients] with relapsed/refractory high-risk neuroblastoma."

Mustafa Khasraw, MD, discusses a follow-up trial to the VERTU study for patient with methylated or unmethylated MGMT glioblastoma who responded well to temozolomide chemotherapy and radiation.

An autologous dendritic cell vaccine consisting of autologous dendritic cells loaded with autologous tumor-associated antigens demonstrated promising survival findings in patients with newly diagnosed glioblastoma, according to updated data from a year-end analysis of an ongoing phase II clinical trial.

The FDA has approved selumetinib for the treatment of pediatric patients, aged 2 years and above, with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Paxalisib had a strong signal of clinical efficacy in patients with newly diagnosed glioblastoma, according to the interim analysis of a phase II clinical trial. Survival was compared to previous data on the FDA-approved standard of care, temozolomide, from another study. Although the comparison of different studies is not precise, the magnitude of numerical difference in survival provides evidence that this agent may extend life in patients with glioblastoma, Kazia Therapeutics announced in a press release. 

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

A Biologics License Application has been submitted to the FDA for the potential approval of naxitamab for the treatment of patients with relapsed or refractory high-risk neuroblastoma.

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

In an interview with&nbsp;Targeted Oncology, Kashyap Patel, MD, discussed the COVID-19 pandemic and the implementation of new precautions in his practice as the number of COVID-19 infected persons rises in the state.<br /> &nbsp;